Videos

Reduce clinician burnout by delegating admin tasks to strong support teams and using AI dictation tools to streamline charting and protect personal time.

Personalized treatment decisions for pancreatic neuroendocrine tumors consider patient history, toxicity profiles, and lifestyle preferences for optimal outcomes.

Personalized treatment decisions for pancreatic neuroendocrine tumors consider patient history, toxicity profiles, and lifestyle preferences for optimal outcomes.

Cancer survival reaches 70% at 5 years, as targeted and immunotherapies boost outcomes and shift care toward survivorship and long-term quality of life.

WVU Medicine pioneers nonthermal PEF therapy for metastatic lung nodules, using robotic bronchoscopy to target tumors precisely and potentially boost immune response.

Neoadjuvant chemotherapy increasingly matches upfront debulking outcomes, reducing extreme surgery risks while highlighting why patients still need access to R0 radical resection.

In an interview, Neeta Somaiah, MD, discussed potential areas of exploration in treating gastrointestinal stromal tumors.

New data links PARP maintenance after recurrence to higher AML/MDS risk and shorter survival, pushing most use to frontline therapy.

Precision drugs, immunotherapy, and radiosurgery transform brain metastases care, extending survival years as teams tackle adverse effects.

Molecular profiling guides ovarian cancer maintenance: HRD and BRCA results steer PARP inhibitors, bevacizumab choices, and patient counseling.

Explore treatment options for pancreatic neuroendocrine tumors, focusing on patient goals, disease pace, and innovative therapies for optimal outcomes.

Patients with cancer avoid risky hair vitamins: review supplements for drug interactions, and consider topical minoxidil for proven, safer regrowth.

Understanding the prognosis of pancreatic neuroendocrine tumors reveals critical factors influencing treatment options and patient outcomes.

Cancer patients battling treatment-related hair loss often try biotin, but it rarely helps and can distort critical lab tests guiding oncology decisions.

In an interview on the first-in-human phase 1 study of gintemetostat, Saad Z. Usmani, MD, PhD, detailed the initial safety and efficacy findings for this oral therapy in patients with heavily pretreated, late-relapsed multiple myeloma.

Trilaciclib reshapes SCLC supportive care by protecting bone marrow from chemo, reducing anemia and thrombocytopenia, and improving treatment tolerance and quality of life.

New targeted drugs transform HER2, ROS1 and ALK lung cancer care, boosting brain response and survival—while precision choices still matter.

South Florida’s diverse lung cancer cases fuel genomic breakthroughs, push screening beyond smokers, and accelerate 2026 targeted-therapy progress.

Although not as essential as in other tumor types, genomic testing is increasingly playing a role in guiding treatment for advanced sarcoma.

NCCN updates recommend cabozantinib for neuroendocrine tumors, offering flexibility in treatment options based on patient needs and prior therapies.

t-MDS treatments boost remission with HMA combinations, yet overall survival still lags; experts await breakthrough therapies that extend life and preserve quality of life.

Azacitidine plus venetoclax boosts response rates in therapy-related high-risk MDS, enabling transplant bridging despite frequent severe cytopenias and infection risk.

Explore why therapy-related high-risk MDS resists standard HMAs and how azacitidine plus venetoclax aims to improve outcomes and bridge to transplant.

Discover the latest insights on axatilimab and belimumab for chronic GVHD, highlighting efficacy, safety, and innovative treatment combinations.

Explore the complexities of treating advanced pancreatic neuroendocrine tumors, focusing on patient care, treatment strategies, and quality of life.

Dr. Shaheen discusses a complex pancreatic neuroendocrine tumor case, emphasizing tailored treatment goals that balance tumor control and quality of life.

Explore the latest advancements in treating sclerotic skin disease and pulmonary involvement with effective therapies like axatilimab and belumosudil.

Dr. Mukherjee explores the future of antibody-drug conjugates in GI cancers, emphasizing precision medicine and targeted therapies for optimal patient outcomes.

Clinicians explore the shift towards earlier use of antibody-drug conjugates in GI oncology, aiming to enhance patient outcomes and treatment efficacy.

Recent trials reveal promising advancements in targeted therapies for chondrosarcomas and tenosynovial giant cell tumors.